Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study

BACKGROUND: Traumatic brain injury is a leading cause of death and disability worldwide. The nitric oxide synthase inhibitor Ronopterin was shown to improve clinical outcome by enhancing neuroprotection in a phase IIa trial. METHODS/DESIGN: The NOSTRA phase III trial (Ronopterin in traumatic brain i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tegtmeier, Frank, Schinzel, Reinhard, Beer, Ronny, Bulters, Diederik, LeFrant, Jean-Yves, Sahuquillo, Joan, Unterberg, Andreas, Andrews, Peter, Belli, Antonio, Ibanez, Javier, Lagares, Alfonso, Mokry, Michael, Willschke, Harald, Flühe, Charlotte, Schmutzhard, Erich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961322/
https://www.ncbi.nlm.nih.gov/pubmed/31937347
http://dx.doi.org/10.1186/s13063-019-3965-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961322/
https://www.ncbi.nlm.nih.gov/pubmed/31937347
http://dx.doi.org/10.1186/s13063-019-3965-4

Ejemplares similares